Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer

Completed · Phase 1

Conditions studied: Hematologic Malignancy, Malignant Lymphoma

In brief

The purpose of this study is to evaluate the effect and safety of multiple doses of ketoconazole on the pharmacokinetics of romidepsin after a single intravenous (IV) infusion.

Key facts

Study ID

NCT01324310

Run by

Celgene

People needed

15

Starts

2011-04-01

Expected to finish

2012-01-01

Last updated by the study team

2019-11-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males and females 18 years of age or older at the time of signing the informed consent document.
• Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted.
• Able to adhere to the study visit schedule and other protocol requirements.
• Must have diagnosis of advanced malignancy and must have failed other available therapies considered standard of care for their disease.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
• Negative urine or serum pregnancy test on females of childbearing potential; and
• All females of childbearing potential must use an effective barrier method of contraception (either an intrauterine contraceptive device [IUCD] or double barrier method using condoms or a diaphragm plus spermicide) during the treatment period and for at least 1 month thereafter. Male subjects should use a barrier method of contraception during the treatment period and for at least 3 months thereafter. Female subjects should avoid the use of estrogen-containing contraceptives, since romidepsin may reduce the effectiveness of estrogen-containing contraceptives. An in vitro binding assay determined that romidepsin competes with β-estradiol for binding to estrogen receptors.

You may not qualify if…

• Any significant medical condition or psychiatric illness that would prevent the subject from participating in the study.
• Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.
• Subjects with significant gastrointestinal disease that may impair drug absorption, such as subjects with a history of Cohn's disease, colectomy, gastrectomy, celiac disease, or other diseases with known malabsorption.
• Serum potassium < 3.8 mmol/L or serum magnesium < 0.85 mmol/L (magnesium converts to 2.1 mg/dl or 1.7 mEq/L) (electrolyte abnormalities can be corrected with supplementation to meet inclusion criteria).
• Concomitant use of drugs that may cause a significant prolongation of the corrected measurement of the time between the start of the cardiac Q wave and the end of the T wave (QTc).
• Concomitant use of Cytochrome P 450 3A4 (CYP3A4) strong inhibitors within 1 week of trial medications.
• Concomitant use of CYP3A4 strong inducers within 2 weeks of trial medications.
• Concomitant use of therapeutic warfarin due to a potential drug interaction. Use of a low dose of warfarin or another anticoagulant to maintain patency of venous access port and cannulas is permitted.
• Clinically significant active infection.
• Known infection with Human Immunodeficiency Virus (HIV), hepatitis B, or hepatitis C.
• Inadequate bone marrow or other organ function as evidenced by:
• Hemoglobin < 9 g/dL (transfusions and/or erythropoietin are permitted);
• Absolute neutrophil count (ANC) ≤ 1.0 * 10\^9 cells/L [subjects with neutropenia (ANC 1-1.5) as a function of their disease may be supported with granulocyte-colony stimulating factor (G-CSF)];
• Platelet count < 100 * 10\^9 cells/L or platelet count < 75 * 10\^9 cells/L if bone marrow disease involvement is documented;
• Total bilirubin > 1.5 * upper limit of normal (ULN) or > 2.0 * ULN in the presence of demonstrable liver metastases;
• Serum aspartate transaminase/serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine transaminase/serum glutamic pyruvic transaminase (ALT/SGPT) > 1.5 * ULN or > 2.0 * ULN in the presence of demonstrable liver metastases; or
• Serum creatinine > 2.0 * ULN;
• Prior chemotherapy treatment within 3 weeks prior to the first day of romidepsin treatment (6 weeks for nitrosoureas) or prior treatment with an investigational agent within 4 weeks prior to the first day of romidepsin treatment.
• Prior radiotherapy within 4 weeks prior to the first day of treatment. Subjects who have not fully recovered or whose acute toxicity related to prior radiotherapy has not returned to baseline are ineligible.
• Major surgery within 2 weeks of study entry (day 1).
• Concomitant use of any other anti-cancer therapy.
• Concomitant use of any investigational agent.
• Prior exposure to romidepsin (other histone deacetylase[HDAC] inhibitors are allowed).
• Any known cardiac abnormalities, such as:
• Congenital long measure of the time between the start of the Q wave and the end of the T wave (QT) syndrome;

Where it is running

• Florida Cancer Specialists — Sarasota, Florida, United States
• Sarah Cannon Research Institute — Nashville, Tennessee, United States
• Sarah Cannon Research UK — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.